Search - tctmd.com

Displaying 1 - 20 of 69

Sort: Relevancy | Date

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation ESC 2016

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Presenter: Zuzana Motovska

August 30, 2016

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

Presentation

CRUSH: Crushed Prasugrel Tablets in STEMI Patients Undergoing Primary PCI

Presenter: Fabiana Rollini

March 28, 2016

Presentation TCT 2015

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

Presenter: Steven R. Bailey, Patrick W. Serruys, Renato Valenti

October 15, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Presenter: Eric Boersma, E. Magnus Ohman, Giuseppe Biondi-Zoccai

October 12, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

Presentation

RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI

Presenter: R. Valenti

September 17, 2015

Presentation

Predictors of Bleeding in ACS Patients Treated With Prasugrel

Presenter: P. Widimsky

June 19, 2015

Presentation

Concomitant PPI Use, Platelet Activity, and Clinical Outcomes in ACS Patients Treated With Prasugrel vs Clopidogrel and Managed Without Revascularization

Presenter: Jose Carlos Nicolau

June 17, 2015

Presentation

Comparison of Ticagrelor vs Prasugrel to Prevent Periprocedural Myonecrosis in ACS

Presenter: Laurent Bonello

June 03, 2015

Presentation

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

Presenter: Usman Baber

May 11, 2015

Presentation

VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel

Presenter: J.M. Cubero

October 06, 2014

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Presenter: Armando P?rez de Prado

September 16, 2014

Presentation TCT 2014

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Presenter: Jos? Mar?a Cubero G?mez

September 16, 2014

Advertisement

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

CRUSH: Crushed Prasugrel Tablets in STEMI Patients Undergoing Primary PCI

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Lessons From the TAXUS Liberté/Prasugrel Substudy

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI

Predictors of Bleeding in ACS Patients Treated With Prasugrel

Concomitant PPI Use, Platelet Activity, and Clinical Outcomes in ACS Patients Treated With Prasugrel vs Clopidogrel and Managed Without Revascularization

Comparison of Ticagrelor vs Prasugrel to Prevent Periprocedural Myonecrosis in ACS

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

VerifyNow in DIabetes High On-Treatment Platelet Reactivity: Switching from Clopidogrel to Prasugrel

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content